Cargando…

The clinical features and prognoses of anti-MDA5 and anti-aminoacyl-tRNA synthetase antibody double-positive dermatomyositis patients

OBJECTIVE: To explore the clinical features and prognoses of dermatomyositis (DM) associated with a double-positive anti-MDA5 and anti-aminoacyl-tRNA synthetase (anti-ARS) antibody presentation. METHODS: We retrospectively analyzed 1280 consecutive patients with idiopathic inflammatory myopathy (IIM...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xixia, Zhang, Lu, Jin, Qiwen, Lu, Xin, Lei, Jieping, Peng, Qinglin, Wang, Guochun, Ge, Yongpeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468482/
https://www.ncbi.nlm.nih.gov/pubmed/36110863
http://dx.doi.org/10.3389/fimmu.2022.987841
_version_ 1784788420856381440
author Chen, Xixia
Zhang, Lu
Jin, Qiwen
Lu, Xin
Lei, Jieping
Peng, Qinglin
Wang, Guochun
Ge, Yongpeng
author_facet Chen, Xixia
Zhang, Lu
Jin, Qiwen
Lu, Xin
Lei, Jieping
Peng, Qinglin
Wang, Guochun
Ge, Yongpeng
author_sort Chen, Xixia
collection PubMed
description OBJECTIVE: To explore the clinical features and prognoses of dermatomyositis (DM) associated with a double-positive anti-MDA5 and anti-aminoacyl-tRNA synthetase (anti-ARS) antibody presentation. METHODS: We retrospectively analyzed 1280 consecutive patients with idiopathic inflammatory myopathy (IIM). Individuals with anti-MDA5 and anti-ARS antibodies (anti-MDA5+/ARS+) were compared to anti-MDA5-/ARS+ and anti-MDA5+/ARS- control individuals based on clinical, pulmonary radiological characteristics, treatment, and follow-up information. RESULTS: Six individuals (0.47%) presented with anti-MDA5+/ARS+; of these, 2 (33.3%) were anti-PL-12+, 2 (33.3%) were anti-Jo-1+, 1 (16.7%) was anti-EJ+, and 1 (16.7%) was anti-PL-7+. Hallmark cutaneous manifestations, including Gottron’s sign (100%), heliotrope rash (50%), mechanic’s hand (66.7%), and skin ulcers (16.7%) were common. Anti-MDA5+/ARS+ patients tended to have higher ferritin levels (p = 0.038) than anti-MDA5-/ARS+ group, and higher CD4+ T-cell counts (p = 0.032) compared to the anti-MDA5+/ARS- group. Radiologically, NSIP with OP overlap was predominant (60%). Consolidation (60%), ground-glass attenuation (GGA) (80%), traction bronchiectasis (80%), and intralobular reticulation (100%) were common in anti-MDA5+/ARS+ individuals. All were diagnosed with ILD and 50% were categorized as RPILD. All patients received glucocorticoids combined with one or more immunosuppressants. Most (83.3%) had a good prognosis following treatment, but there was no difference in the survival rate between the three subgroups. CONCLUSION: Presentation with anti-MDA5+/ARS+ DM was rare. The clinical and radiological characteristics of anti-MDA5+/ARS+ DM combined the features of anti-MDA5+ and anti-ARS+ individuals. Individuals with anti-MDA5+/ARS+ antibodies may respond well to glucocorticoid therapy; glucocorticoids combined with one or more immunosuppressants may be considered a basic treatment approach.
format Online
Article
Text
id pubmed-9468482
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94684822022-09-14 The clinical features and prognoses of anti-MDA5 and anti-aminoacyl-tRNA synthetase antibody double-positive dermatomyositis patients Chen, Xixia Zhang, Lu Jin, Qiwen Lu, Xin Lei, Jieping Peng, Qinglin Wang, Guochun Ge, Yongpeng Front Immunol Immunology OBJECTIVE: To explore the clinical features and prognoses of dermatomyositis (DM) associated with a double-positive anti-MDA5 and anti-aminoacyl-tRNA synthetase (anti-ARS) antibody presentation. METHODS: We retrospectively analyzed 1280 consecutive patients with idiopathic inflammatory myopathy (IIM). Individuals with anti-MDA5 and anti-ARS antibodies (anti-MDA5+/ARS+) were compared to anti-MDA5-/ARS+ and anti-MDA5+/ARS- control individuals based on clinical, pulmonary radiological characteristics, treatment, and follow-up information. RESULTS: Six individuals (0.47%) presented with anti-MDA5+/ARS+; of these, 2 (33.3%) were anti-PL-12+, 2 (33.3%) were anti-Jo-1+, 1 (16.7%) was anti-EJ+, and 1 (16.7%) was anti-PL-7+. Hallmark cutaneous manifestations, including Gottron’s sign (100%), heliotrope rash (50%), mechanic’s hand (66.7%), and skin ulcers (16.7%) were common. Anti-MDA5+/ARS+ patients tended to have higher ferritin levels (p = 0.038) than anti-MDA5-/ARS+ group, and higher CD4+ T-cell counts (p = 0.032) compared to the anti-MDA5+/ARS- group. Radiologically, NSIP with OP overlap was predominant (60%). Consolidation (60%), ground-glass attenuation (GGA) (80%), traction bronchiectasis (80%), and intralobular reticulation (100%) were common in anti-MDA5+/ARS+ individuals. All were diagnosed with ILD and 50% were categorized as RPILD. All patients received glucocorticoids combined with one or more immunosuppressants. Most (83.3%) had a good prognosis following treatment, but there was no difference in the survival rate between the three subgroups. CONCLUSION: Presentation with anti-MDA5+/ARS+ DM was rare. The clinical and radiological characteristics of anti-MDA5+/ARS+ DM combined the features of anti-MDA5+ and anti-ARS+ individuals. Individuals with anti-MDA5+/ARS+ antibodies may respond well to glucocorticoid therapy; glucocorticoids combined with one or more immunosuppressants may be considered a basic treatment approach. Frontiers Media S.A. 2022-08-30 /pmc/articles/PMC9468482/ /pubmed/36110863 http://dx.doi.org/10.3389/fimmu.2022.987841 Text en Copyright © 2022 Chen, Zhang, Jin, Lu, Lei, Peng, Wang and Ge https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Chen, Xixia
Zhang, Lu
Jin, Qiwen
Lu, Xin
Lei, Jieping
Peng, Qinglin
Wang, Guochun
Ge, Yongpeng
The clinical features and prognoses of anti-MDA5 and anti-aminoacyl-tRNA synthetase antibody double-positive dermatomyositis patients
title The clinical features and prognoses of anti-MDA5 and anti-aminoacyl-tRNA synthetase antibody double-positive dermatomyositis patients
title_full The clinical features and prognoses of anti-MDA5 and anti-aminoacyl-tRNA synthetase antibody double-positive dermatomyositis patients
title_fullStr The clinical features and prognoses of anti-MDA5 and anti-aminoacyl-tRNA synthetase antibody double-positive dermatomyositis patients
title_full_unstemmed The clinical features and prognoses of anti-MDA5 and anti-aminoacyl-tRNA synthetase antibody double-positive dermatomyositis patients
title_short The clinical features and prognoses of anti-MDA5 and anti-aminoacyl-tRNA synthetase antibody double-positive dermatomyositis patients
title_sort clinical features and prognoses of anti-mda5 and anti-aminoacyl-trna synthetase antibody double-positive dermatomyositis patients
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468482/
https://www.ncbi.nlm.nih.gov/pubmed/36110863
http://dx.doi.org/10.3389/fimmu.2022.987841
work_keys_str_mv AT chenxixia theclinicalfeaturesandprognosesofantimda5andantiaminoacyltrnasynthetaseantibodydoublepositivedermatomyositispatients
AT zhanglu theclinicalfeaturesandprognosesofantimda5andantiaminoacyltrnasynthetaseantibodydoublepositivedermatomyositispatients
AT jinqiwen theclinicalfeaturesandprognosesofantimda5andantiaminoacyltrnasynthetaseantibodydoublepositivedermatomyositispatients
AT luxin theclinicalfeaturesandprognosesofantimda5andantiaminoacyltrnasynthetaseantibodydoublepositivedermatomyositispatients
AT leijieping theclinicalfeaturesandprognosesofantimda5andantiaminoacyltrnasynthetaseantibodydoublepositivedermatomyositispatients
AT pengqinglin theclinicalfeaturesandprognosesofantimda5andantiaminoacyltrnasynthetaseantibodydoublepositivedermatomyositispatients
AT wangguochun theclinicalfeaturesandprognosesofantimda5andantiaminoacyltrnasynthetaseantibodydoublepositivedermatomyositispatients
AT geyongpeng theclinicalfeaturesandprognosesofantimda5andantiaminoacyltrnasynthetaseantibodydoublepositivedermatomyositispatients
AT chenxixia clinicalfeaturesandprognosesofantimda5andantiaminoacyltrnasynthetaseantibodydoublepositivedermatomyositispatients
AT zhanglu clinicalfeaturesandprognosesofantimda5andantiaminoacyltrnasynthetaseantibodydoublepositivedermatomyositispatients
AT jinqiwen clinicalfeaturesandprognosesofantimda5andantiaminoacyltrnasynthetaseantibodydoublepositivedermatomyositispatients
AT luxin clinicalfeaturesandprognosesofantimda5andantiaminoacyltrnasynthetaseantibodydoublepositivedermatomyositispatients
AT leijieping clinicalfeaturesandprognosesofantimda5andantiaminoacyltrnasynthetaseantibodydoublepositivedermatomyositispatients
AT pengqinglin clinicalfeaturesandprognosesofantimda5andantiaminoacyltrnasynthetaseantibodydoublepositivedermatomyositispatients
AT wangguochun clinicalfeaturesandprognosesofantimda5andantiaminoacyltrnasynthetaseantibodydoublepositivedermatomyositispatients
AT geyongpeng clinicalfeaturesandprognosesofantimda5andantiaminoacyltrnasynthetaseantibodydoublepositivedermatomyositispatients